Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M33.3Revenue $M13.0Net Margin (%)-238.4Altman Z-Score-8.8
Enterprise Value $M5.4EPS $-0.2Operating Margin %-231.5Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.1Pre-tax Margin (%)-242.5Higher ROA y-yN
Price/Book1.610-y EBITDA Growth Rate %-29.8Quick Ratio4.7Cash flow > EarningsY
Price/Sales8.25-y EBITDA Growth Rate %-14.1Current Ratio4.7Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-83.8Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-154.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M68.0ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with PTN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PTNFirst Eagle Investment 2013-06-30 Sold Out $0.578 - $0.67
($0.61)
$ 0.49-20%Sold Out0
PTNFirst Eagle Investment 2013-03-31 Reduce$0.551 - $0.68
($0.62)
$ 0.49-21%Reduce -84.35%121,094
PTNFirst Eagle Investment 2012-09-30 Reduce$0.48 - $0.75
($0.66)
$ 0.49-26%Reduce -53.47%773,660
PTNFirst Eagle Investment 2011-12-31 Add$0.4019 - $0.6789
($0.55)
$ 0.49-11%Add 72.72%1,662,543
PTNFirst Eagle Investment 2011-09-30 Add$0.5032 - $1.14
($0.84)
$ 0.49-42%Add 35.10%962,543
PTNFirst Eagle Investment 2011-06-30 Reduce-0.01%$0.82 - $1.08
($0.9)
$ 0.49-46%Reduce -54.36%712,443
PTNFirst Eagle Investment 2011-03-31 Add0.01%$0.8 - $1.4
($1.09)
$ 0.49-55%Add 1441.78%1,560,895
PTNFirst Eagle Investment 2010-06-30 Reduce$1.8 - $3.2
($2.65)
$ 0.49-82%Reduce -24.39%114,967
PTNKen Fisher 2010-06-30 Sold Out $1.8 - $3.2
($2.65)
$ 0.49-82%Sold Out0
PTNFirst Eagle Investment 2009-12-31 Reduce$2.4 - $3.9
($3.05)
$ 0.49-84%Reduce -8.98%152,062
PTNFirst Eagle Investment 2009-09-30 Reduce$2.2 - $3.8
($3.05)
$ 0.49-84%Reduce -44.74%167,062
PTNFirst Eagle Investment 2009-06-30 Reduce$1.1 - $3.5
($2.1)
$ 0.49-77%Reduce -15.24%302,309
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PTN is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


PTN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Hull Joseph StanleyDirector 2015-12-04Buy2,500$0.66-25.76view
Hull Joseph StanleyDirector 2015-11-19Buy2,000$0.65-24.62view
DEVEER ROBERT K JRDirector 2015-10-02Buy10,000$0.82-40.24view
BVF PARTNERS L P/IL10% Owner 2014-02-27Sell293,825$1.09-55.05view
BVF PARTNERS L P/IL10% Owner 2014-02-26Sell540,181$1.14-57.02view
BVF PARTNERS L P/IL10% Owner 2014-02-19Sell305,966$1.17-58.12view
DUNTON ALAN WDirector 2013-03-19Buy1,000$0.58-15.52view
DUNTON ALAN WDirector 2013-02-01Buy2,000$0.59-16.95view
TABER ROBERT IDirector 2013-01-28Buy5,000$0.59-16.95view
SPANA CARLPresident & CEO 2012-12-31Buy10,000$0.57-14.04view

Quarterly/Annual Reports about PTN:

News about PTN:

Articles On GuruFocus.com
Chuck Royce Cuts Second Largest Communications Equipement Holding Jul 07 2015 

More From Other Websites
PALATIN TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report Feb 12 2016
Should You Buy Palatin Technologies (PTN) Ahead of Earnings? Feb 12 2016
Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2016 Results Feb 10 2016
Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female... Feb 08 2016
Palatin Technologies To Present At The BIO CEO & Investor Conference Feb 04 2016
PALATIN TECHNOLOGIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Dec 11 2015
Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide... Dec 10 2015
Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide... Dec 10 2015
PALATIN TECHNOLOGIES INC Financials Dec 08 2015
Vringo, Inc. (VRNG): Are Hedge Funds Right About This Stock? Nov 29 2015
PALATIN TECHNOLOGIES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 12 2015
PALATIN TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report Nov 12 2015
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2016 Results Nov 12 2015
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2016 Results; Teleconference and... Nov 12 2015
Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2016 Results Nov 10 2015
Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2016 Results; Teleconference and... Nov 10 2015
The world's first female sex drug could spur similar meds Oct 16 2015
The world's first female sex drug could spur similar meds Oct 16 2015
Palatin Technologies, Inc. Earnings Q4, 2015 Oct 01 2015
Preclinical Data on PL-3994 for Heart Failure and Resistant Hypertension Presented at 2015 Heart... Sep 28 2015

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK